Last updated on October 2018

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly


Brief description of study

Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated sustained biochemical response up to 13 months in patients with acromegaly previously managed with somatostatin analog injections (ref).

The purpose of this study is to compare the efficacy safety and patient reported outcomes between oral octreotide capsules and injectable somatostatin analogs.

Detailed Study Description

This will be a phase 3, randomized, open-label, active controlled, multicenter study to evaluate maintenance of response, safety and patient reported outcomes (PROs) in acromegaly patients treated with octreotide capsules and in patients treated with SOC parenteral SRLs, who previously tolerated and demonstrated biochemical control on both treatments.

The core study will consist of three phases: a Screening phase, Run-in phase and a Randomized Controlled Treatment Phase (RCT).

Eligible patients who are biochemically controlled on parenteral SRLs will be switched to octreotide capsules for a 26-week Run-in phase. During this phase the effective dose for each patient will be determined through dose titration.

Patients whose acromegaly is been controlled biochemically on octreotide capsules at the end of the Run-in Phase will enter a 36-week open-label Randomized Controlled Treatment Phase, where they will be randomized to continue on octreotide capsules or switch back to their injectable SRL treatment (as received prior to Screening).

Following the completion of the core study (Screening, Run-in and RCT phases), eligible patients will be offered to enter the Study Extension phase and receive octreotide capsules until product marketing or study termination.

A Sub-study, in selected sites, would allow patients with in-adequate biochemical control on octreotide capsules during the Run-in Phase to enter a Combination phase and receive co-administration of octreotide capsules with cabergoline tablets for a total of 36 weeks.

Clinical Study Identifier: NCT02685709

Contact Investigators or Research Sites near you

Start Over

Engage Health

University of Alabama at Birmingham
Birmingham, AL United States

Engage Health

Keck Medical Center of University of Southern California
Los Angeles, CA United States

Engage Health

Cedars-Sinai Medical Center
Los Angeles, CA United States

Engage Health

Stanford University School of Medicine
Stanford, CA United States

Engage Health

University of Colorado Denver
Aurora, CO United States

Engage Health

Emory University
Atlanta, GA United States

Engage Health

Northwestern University
Chicago, IL United States

Engage Health

John H. Stroger, Jr. Hospital of Cook County
Chicago, IL United States

Engage Health

Johns Hopkins University
Baltimore, MD United States

Engage Health

Massachusetts General Hospital
Boston, MA United States

Engage Health

Washington University School of Medicine
Saint Louis, MO United States

Engage Health

Palm Research Center, Inc.
Las Vegas, NV United States

Engage Health

Rutgers - Robert Wood Johnson Medical School
New Brunswick, NJ United States

Engage Health

Columbia University Medical Center
New York, NY United States

Engage Health

The Ohio State University Wexner Medical Center
Columbus, OH United States

Engage Health

Thomas Jefferson University
Philadelphia, PA United States

Engage Health

Allegheny Endocrinology Associates
Pittsburgh, PA United States

Engage Health

Midstate Endocrinology Associates
Nashville, TN United States

Engage Health

Baylor College of Medicine
Houston, TX United States

Engage Health

Houston Methodist Research Institute
Houston, TX United States

Barbara Obermayer-Pietsch, MD

Universit tsklinik f r Innere Medizin Klinische Abteilung f r Endokrinologie und Diabetologie
Graz, Austria

Anton Luger, MD, PhD

Medizinische Universit t Wien
Wien, Austria

Gerald Raverot, MD, PhD

Hospices Civils de Lyon
Bron, France

Engage Health

Praxis f r Endokrinologie und Diabetologie Dr M Droste
Oldenburg, Germany

Engage Health

Magyar Honvedseg Egeszsegugyi Kozpont
Budapest, Hungary

Engage Health

University of Pecs
Pecs, Hungary

Engage Health

Szegedi Tudom nyegyetem, I. Belgy gy szati Klinika
Szeged, Hungary

Engage Health

Policlinico di Monserrato U.O.C. Endocrinologia e Diabetologia
Monserrato, Italy

Engage Health

Universit di Pisa Dipartimento di Medicina Clinica e Sperimentale
Pisa, Italy

Engage Health

Fondazione Policlinico Universitario A. Gemelli Universit Cattolica del S.Cuore S.C. Endocrinologia e Malattie del Metabolismo
Rome, Italy

Robertas Knispelis, MD

Hospital of LUHS Kauno Klinikos
Kaunas, Lithuania

Vaidotas Urbanavicius, MD, PhD

Vaidotas Urbanavicius Individuali Imon
Vilnius, Lithuania

Phillipe Chanson, MD, PhD

H pital Bic tre APHP
Le Kremlin-Bicêtre, France

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.